Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 24 Analysts

1S.Buy

22Buy

1Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$191Upside to Avg. PT-8.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	Brookline Capital	Leah Rush	Initiate	Buy	$318
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$267
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$225→$265
Sep 10, 2026	Morgan Stanley	Sean Laaman	Initiate	Overweight	$255
Sep 9, 2026	Stifel	Laura Prendergast	PT Raise	Buy	$215→$230
Aug 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$240→$275
Aug 28, 2026	UBS	Michael Yee	PT Raise	Buy	$220→$265
Aug 28, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$240→$275
Aug 27, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$230→$260
Aug 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$203→$251
Aug 27, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$201→$225
Aug 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$231→$239
Aug 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$230→$320
Aug 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$195→$280
Aug 21, 2026	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$151→$179
Aug 11, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$210→$231
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$182→$203
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$192→$201
Aug 6, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$220→$230
Aug 6, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$235→$240

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.

Benzinga Newsdesk

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.

Benzinga Newsdesk

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price

Avi Kapoor

Revolution Medicines Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

PRO
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

Revolution Medicines Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBrookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PROGoldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PROB of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PROMorgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

PROStifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

PRO
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

PRO
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

PRO
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

PRO
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255

PRO
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230